Axitinib exposure triggers endothelial cells senescence through ROS accumulation and ATM activation
Ontology highlight
ABSTRACT: Here we report that Axitinib, an inhibitor of VEGFRs currently in use as a second line treatment for advanced renal cell carcinoma, promotes senescence of human endothelial cells in vitro. Mechanistically, this requires oxidative stress-dependent activation of the Ataxia Telangiectasia Mutated (ATM) kinase. Induction of oxidative stress-related genes distinguishes the response of endothelial cells to Axitinib from that to doxorubicin
ORGANISM(S): Homo sapiens
PROVIDER: GSE126426 | GEO | 2019/07/02
REPOSITORIES: GEO
ACCESS DATA